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Abstract. Infection with human papillomavirus (HPV) presents a serious problem for modern healthcare. The most 
common manifestations of the papillomavirus infection include anogenital warts, cervical intraepithelial neoplasia, 
cervical cancer. The purpose of the work is to determine the economic feasibility of preventing cervical cancer in 
Ukraine by introducing a continuous vaccination against a papilloma virus infection. Markov simulation was used to 
determine the incremental cost-effectiveness ratio (ICER) based on epidemiological data on morbidity and mortality 
from cervical cancer in Ukraine. Taking into account the accepted assumptions and limitations of the introduction of 
HPV vaccination in Ukraine, it will prevent 1380 cervical cancer cases, preserve 2058 quality-adjusted life years and 
the reduce the cost of medical care for cervical cancer in the amount of $1,479,972. The amount of additional costs for 
the vaccine and its introduction is $12,009,684 (all results per 100,000 vaccinated persons). The ICER index is 
$4,729, which is 1.4 times higher the gross domestic product in Ukraine per 1 person in 2019 ($3,464). Taking into 
account the actual cost of the vaccine, vaccination against HPV infection with a view of preventing cervical cancer in 
Ukraine is currently economically feasible. 
Keywords: Human papillomavirus, vaccination, Markov simulation, economic feasibility, Ukraine 
                                                          
* gsmlk@ukr.net 
1. INTRODUCTION 
Infection with human papillomavirus (HPV) 
presents a serious problem for modern health care. 
About 2.5-3 million cases of infection are diagnosed 
annually in the world. The most common 
manifestations of the papillomavirus infection include 
anogenital warts, cervical intraepithelial neoplasia, 
cervical cancer, vulvar and vaginal cancer. According to 
World Health Organization (WHO), up to 82% of 
women are infected with different types of HPV two 
years after sexual intercourse. HPV causes cervical 
cancer, which is the most common cancer in women, 
with estimated 266,000 deaths and 528,000 new cases 
in 2012. A large majority (about 85%) of the global 
burden occurs in developed regions, where it accounts 
for almost 12% of all female cancers [1, 2, 3]. The only 
way to effectively prevent HPV-associated diseases is 
the vaccine prophylaxis. Three HPV vaccines are now 
being marketed in many countries throughout the 
world - a bivalent, a quadrivalent, and nonavalent 
vaccines. All three vaccines are highly efficacious in 
preventing infection with virus types 16 and 18, which 
are together responsible for approximately 70% of 
cervical cancer cases globally [4, 5, 6]. 
According to numerous scientific studies, after 
vaccination, the frequency of detection of HPV 16 and 
type 18 decreases [7, 8]. According to meta-analyzes, 
68% and provided 80% of girls were vaccinated, the 
previous reduction of HPV 16 among women and men 
was 93% [9, 10, 11]. 
In May 2018, 81 countries (42% of UN Member 
States, corresponding to 25% of target population) had 
introduced HPV to the national routine immunization 
schedules [12]. Cost-effective vaccination against HPV 
has been proven in many countries [13, 14, 15, 16, 17, 
18]. However, due to different indicators of social-
economic development, it is not always possible to use 
the results of an assessment of a particular medical 
technology conducted in other states [19]. Therefore, 
one of the topical issues is the study of the possibility of 
including vaccination against a papillomavirus 
infection in a mandatory vaccination calendar in 
Ukraine. 
HPV-associated diseases and, in particular, cervical 
cancer is a significant health problem in Ukraine. 
According to the National Cancer Registry of Ukraine 
(NCRU) [20], in the structure of the incidence of 
women with malignant neoplasia, cervical cancer is 
5.9% (ranked fifth). About 1,700 women (5.8% of 
patients with malignant tumors) die every year from 
the cervical cancer in Ukraine. 
Mortality from cervical cancer is noted in women of 
the most able-bodied period of life, when they are 
actively engaged in raising children, have the 
maximum professional and life experience, participate 
in public life. In addition to the medical and social 
problem of cervical cancer, a major socio-economic 
damage is the precancerous and pre-invasive forms of 
this disease that can lead to infertility and disability. 
Taking into account the above mentioned facts, the 
conduct of this study is very relevant. 
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The purpose of the study – to calculate the 
economic feasibility of cervical cancer prevention by 
vaccination against papillomavirus infection in 
Ukraine. 
2. MATERIALS AND METHODS 
To achieve the purpose of the study, we have used a 
method of analyzing economic feasibility, which allows 
comparing two alternative medical technologies, 
provided that the results of treatment can be measured 
in the same degree of health. 
We carried out simulation of two technologies - 
vaccination against papillomavirus infection of the 
entire cohort of 12-year-old girls in Ukraine (“new” 
technology) and the current situation (without 
vaccination, “comparison” technology). Expenditures 
in both variants (without vaccination and in case of it) 
were evaluated in monetary units. The results of the 
introduction of the “new” health (vaccination) 
technology were assessed using the quality-adjusted 
life-year (QALY) indicator, which is most often used to 
compare the relative improvement in the health of the 
population as a result of the application of a variety of 
health technologies. 
It is economically feasible to have a technology in 
which one unit of incremental health improvement (in 
our case, one QALY) can be achieved at an acceptable 
incremental cost of the “new” technology (in our case, a 
vaccination) to an alternative to comparison (the 
current situation without vaccination) (Formula 1). 
ICER = (C2 – C1) / (QALY2 – QALY1) (1),  
where ICER is an incremental cost-effectiveness ratio; 
С2 - costs for “new” technology in monetary units; С1 - 
costs of comparative technology (as a rule existing); 
QALY2 - the number of years of quality of life when 
using the “new” technology; QALY1 - the number of 
years of quality life when using the technology of 
comparison. 
The study was conducted considering the long-term 
social perspective, the definition of economic feasibility 
was carried out using the Markov modeling method 
[21] in the Microsoft Excel program. The Markov 
model investigates a hypothetical cohort of patients 
who are in the initial state before the study (in our case, 
the “healthy” state) and are converted to different 
states during the cycle according to definite 
probabilities. The patient may be in only one of the 
classes, so each subsequent cycle is determined by the 
number of patients that are distributed by the states. 
This allows you to calculate the costs and quantity of 
QALY during the cycles for each state of the 
investigated technology. 
The study program included the following steps: 
1. Development of the Markov model (the definition 
of the Markov’s states and variants of transition 
between them). 
2. Search for scientific and statistical data to 
calculate the matrix of the probabilities of transition 
between Markov states. 
3. Calculation of the number of QALYs of the cost of 
medical care (direct costs) due to the incidence of 
cervical cancer without vaccination (in the present 
situation, the model of comparison). 
4. Calculation of the number of QALYs and the cost 
of medical care due to the incidence of cervical cancer 
under vaccination (direct costs, based on the cost of 
vaccination - the model of the experiment). 
5. Determination of ICER and decision making on 
recommendations. 
During the simulation, we assumed that 
vaccination was conducted for all 12-year-old girls in 
Ukraine, and the effect of vaccination is maintained 
throughout life. In carrying out the assessment, only 
the effect in the vaccinated population was considered, 
without considering cross-vaccination. Economic 
feasibility was determined only for cervical cancer (the 
effect of vaccination for other diseases that can be 
caused by HPV, due to lack of reliable statistical data, 
was not considered). 
Demographic indicators (the population of females 
under the age of 12 years as of 01.01.2019, the total 
mortality of the population by age) were obtained from 
the site of Statistics of Ukraine [22]. Indicators of age-
related cervical cancer incidence, mortality due to 
cervical cancer, distribution of patients with cervical 
cancer by stages, 5-year survival in cervical cancer, 
depending on the stage of the disease, recurrence rate 
of cervical cancer after treatment, rates of use of 
different types of treatment by stages were obtained 
from the NCRU [20]. 
Necessary amount of funding for diagnosis in the 
stage of cervical cancer, monitoring the severity of 
relapses (for those who are in the stage of remission), 
surgical treatment, chemotherapy and radiotherapy of 
cervical cancer was determined by the data of the 
prices of the private clinic [23], as in the public clinics 
in the Ukraine official payment is not established. The 
cost of the vaccine, vaccination and examination of the 
pediatrician in front of it also determined from the 
websites of private clinics (in Ukraine it is not 
mandatory) [23]. 
Table 1. The matrix of probabilities of transitions between 
Markov states (without vaccination) 
From state 
to state 1.A 2.B 3.C 4.D 
1.A 0.999516 0.000017* 0 0.000467** 
2.B 0 0.12 0.72 0.16 
3.C 0.55 0.22 0.13 0.1 
4.D 0 0 0 1 
Note: * from 1 (A) state to 2 (B) state according to the incidence of 
cervical cancer by age; ** from 1 (A) state to 4 (D) state according to the 
indicators of total mortality by age (without mortality from cervical 
cancer). 
Creating the model, we identified the following 
Markov states for the female population: 1. A - healthy; 
2. B - primary patients with cervical cancer (acute 
period) - receive diagnosis and different types of 
treatment depending on the stage of the disease; 
3. C - cervical cancer patients during remission - need 
to be diagnosed with relapses; 4. D - death. 
Time horizon - the period of survival of girls, who at 
the beginning of the study is 12 years old. The duration 
of the Markov cycle is 1 year. Discounting the duration 
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of life and the amount of costs considered at a rate of 
3% per year. 
Considering the initial data, we determined the 
probabilities of transitions between states, given in 
Table 1 (the model of comparison, when vaccinated, the 
probability of transition from the state 1 (A) to the state 
2 (B) decreases by 65%). 
According to statistics, as of 01.01.2019, in Ukraine 
there were 209 930 girls aged 12 years [22]. The 
indicator of total mortality of the female population in 
all age groups was 13.89 per 1,000 women. The 
standardized incidence rate of female population in the 
cervical cancer in 2018 was 19.3 per 100,000 female 
population, and standardized mortality rate from 
cervical cancer was 7.1 per 100,000 women. The age-
related indicators of overall mortality, morbidity and 
mortality from cervical cancer were used [20, 22]. 
In modeling, we considered that according to the 
data of the NCRU (data for 2019), cervical cancer 
manifests itself in the following stages: I st. and II st. – 
69.6%, III st. – 17.6%, IV st. -7.9%, stage not defined – 
4,5%. The consumption of patients directly depends on 
the stage of the disease, its five-year indicators are for 
stage I – 78.1%, II – 57.0%, III – 31.0%, IV – 7.8%, all 
stages - 55.0% [21]. It was therefore assumed that  
5 years after the discovery of the disease in the absence 
of relapses, 55% of patients from the category 
“remission” went into the category “healthy”. In the 
first year after the diagnosis of cervical cancer in 
Ukraine, about 15.2% of women die. 
According to [20], the rate of recurrence of cervical 
cancer (tumor growth, the appearance of metastases) 
in Ukraine is about 24.0% (transition from the state 3 
(C) to the stage 2 (B), requiring predominantly 
chemotherapeutic treatment). With regard to the 
quality of life factors during stay in different states 
(taken into account when calculating lost QALY), 
taking into account world data, we have taken the 
following: healthy (A) - 0.9, primary ill (acute period) 
(B) - 0.5; patients with cervical cancer in the period of 
remission (C) -0.7, death (D) - 0. 
To calculate the direct costs of diagnosis and 
treatment of cervical cancer, we considered the order of 
the Ministry of Health of Ukraine of 02.04.2014 №236 
“Unified clinical protocol of primary, secondary 
(specialized), tertiary (highly specialized) medical care. 
Dysplasia of the cervix. Cervical cancer” [24], which 
transmits the necessary volume of diagnostic and 
medical services depending on the stage of the disease. 
The cost of diagnosis of the stage of cervical cancer and 
the presence of relapses (for those who are in the stage 
of remission) is determined at a rate of $355.  
This includes a gynecologist’s review, colposcopy, 
biopsy, cytological, histological, ultrasound 
examination, blood tests on oncomarkers, computer 
and magnetic resonance imaging. Diagnosis should be 
performed for all patients with cervical cancer and in 
cases of suspected relapse. Treatment costs were 
determined by us depending on the stage of the 
disease. 
1. Costs for surgical treatment of cervical cancer are 
defined in the amount of $1333 (abdominal or 
laparoscopic removal of the uterus, considering the 
cost of anesthesia and hospital stay). Only surgical 
treatment was performed for 17.0% of the patients first 
diagnosed with cervical cancer. 
2. Expenditures for chemotherapy of cervical 
cancer. Two cycles of neoadjuvant therapy with 
carboplatin and paclitaxel were administered in 50% of 
patients and six adjuvant therapy cycles in 25% of 
patients. The cost of all courses of chemotherapy was 
accepted by us for $1852. 
3. Costs of radiotherapy of cervical cancer were 
about $148, received 40.0% of patients. 
4. Combinations of these methods of treatment 
were used in the provision of medical care in 78.0% of 
patients. 
In general, considering the above data, we 
calculated that the average cost of treatment of one 
case of cervical cancer in terms of direct costs is $4074. 
According to the NCRU [20], 22.0% of patients who 
were diagnosed with cervical cancer were not covered 
by treatment. 
For the given values, we calculated the cost of 
diagnosis and treatment of cervical cancer, as well as 
the number of QALYs from the unvaccinated 
population (model of comparison). 
At the next stage, the calculation was made based 
on the simulation of the vaccination against HPV by a 
bivalent vaccine (it was assumed that vaccination 
reduces the risk of contracting a cervical cancer (the 
probability of transition from state 1 (A) to state  
2 (B))). 
The predicted effectiveness of HPV vaccination in 
the prevention of cervical cancer was determined 
considering that according to research [2, 3, 4, 5, 6], 
the cause of cervical cancer in 74% of cases is HPV 16th 
and 18th types. Consequently, we consider that 
vaccination will reduce the risk of cervical cancer to fall 
by 65% (considering that 88% vaccination reduces the 
presence of HPV in the body). 
Initially, the costs of diagnosis and treatment of 
cervical cancer (for a fraction of those who were ill) 
were calculated, cost estimates for one case were 
identical with the comparison group. At the next stage, 
the cost of vaccination was calculated. The price of a 
bivalent vaccine “Cervarix” was established at $46. It is 
used for children from 9 to 14 years including two 
doses of 0.5 ml. The second dose is administered 
between 5 and 13 months after the first dose. The cost 
of 2 vaccinations is $ 92. It was assumed that before 
the introduction of each dose of the vaccine, the 
pediatrician’s examination is carried out (cost $ 10.1) 
[23]. 
Having got these indices, we calculated the cost of 
vaccination for the entire cohort of 12-year-old girls in 
Ukraine (model of experiment). The number of QALYs 
for the vaccinated population was determined. Based 
on the obtained results, the value of the ICER was 
established. 
During the analysis of sensitivity, the changes of the 
following parameters were evaluated: increasing the 
effectiveness of vaccination in the part of prevention of 
cervical cancer to a level of 85% (from 65%); reduction 
of the cost of the vaccine by 50% (cost $23); and 
increase in the cost of treatment for one case of cervical 
cancer by 50%. 




According to the results of modeling in the first 
variant (preserving the existing situation with regard to 
the incidence of cervical cancer), it has been 
established that in Ukraine during the lifetime of 209 
930 girls, who at the beginning of 2019 were 12 years 
old, with the preservation of existing indicators of 
morbidity, 4459 people (2124 per 100 000 women’s 
population). 
With regard to the simulation of the second option - 
HPV vaccination for all 12-year-old girls, the expected 
reduction in the number of patients with cervical 
cancer to 1563 (out of 4459) (Fig. 1) is expected, which 
is 744 people per 100 000 female population. That is, 
considering the assumptions made, the vaccination of 
100,000 girls with an HPV vaccine will prevent 1380 
cases of cervical cancer. 
 
Figure 1. Comparison of the number of cases of cervical 
cancer in a vaccinated and unvaccinated female population 
(209930 persons) 
 
Figure 2. The number of additional QALYs by age groups 
obtained as a result of vaccination against HPV infection for 
the prevention of cervical cancer for the population of 209 
930 females (with discounting, years). 
With regard to QALY, the first option, due to 
morbidity and premature mortality from cervical 
cancer, has determined that this indicator for a given 
population of 12 years of age will be based on 
discounting (3%) of 5,580,791 years (26.58 years for 
1 person), without discounting – 58.55 years. 
The calculated QALY, with allowance for 
discounting for the cohort of vaccinated persons, will 
be 5 585 112 years, which in the amount of 1 person will 
be 26.60 years (without discounting - 58.63 years). 
According to the simulation, the introduction of 
vaccination will add 4321 QALY (2058 QALY per 
100 000), the greatest number of them will be obtained 
as a result of prevention of the disease in persons aged 
45-64 (Fig. 2). 
The total cost of providing medical care related to 
cervical cancer for unvaccinated persons with a 
discount of 3% will be $4 776 689 ($22.7 per person). 
The total cost of providing medical care related to 
cervical cancer vaccinated persons, considering 
discounting at 3%, will be $1 669 781 ($7,9 per person). 
Consequently, the vaccination will enable to prevent 
the costs associated with the disease in the cervical 
cancer, the vaccinated population (209930 women) to 
$3 106 908 or $1 479 972 per 100,000 female 
population. 
The maximum increase in the prevented costs (with 
discounting) can be predicted at the time of reaching 
the vaccinated age of 35-49 years (Fig. 3). 
 
Figure 3. The size of direct expenses for provision of medical 
care under cervical cancer in age groups, forewarned as a 
result of vaccination against HPV, $, for the population of 
209 930 women (with discounting). 
Table 2. Results of calculation of evaluation of vaccination 












The incidence of 
cervical cancer, per 100 
000 
2124 744 -1380 
Average QALY, per 
person, years (discount 
-3%) 
26.58 26.60 0.02 
Average life expectancy 
after 12 years without 
discount 
58.55 58.63 0.08 
Costs of rendering of 
medical care, which 
relates to cervical 
cancer, per 1 person, $. 
(discount - 3%) 
22.7 7.9 14.8 
Costs for vaccination, $ 
per person 
0 112.1 -112.1 
Average cost per 
person, $ 
22.7 120.0 -97.3 
To these costs, it is necessary to add a cost of 
vaccination (the cost of double-administration of the 
bivalent vaccine, considering the pediatrician’s review 
for the entire cohort of 12-years girls will be 
$23 542150). The total cost for the experiment group 
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will be $25 211 931 ($12 009 685 per 100 000). 
Summarized results of calculation are given in Table 2. 
By the formula given above, we have determined 
the ICER (cost of one additional QALY) when 
vaccinated with a divalent vaccine. 
ICER = ($25 211 931– $4 776 689) / (5 585 112 - 
5 580 791) = $ 4729 
We have analyzed the sensitivity of individual 
parameters, which may vary depending on various 
factors, or there are different data in scientific sources. 
The results of the analysis of the sensitivity of the 
results to the change in modeling parameters are 
shown in Table 3. 














efficiency in the prevention 
of cervical cancer to the 
level 85% (from 65%) 
3452 1.0 
Reducing the cost of a 
vaccine by 50% (cost $ 23) 
2473 0.7 
An increase in the cost of 
cervical cancer by 50% 
4379 1.3 
4. DISCUSSION 
In countries with economics in transition 
(including Ukraine), where pharmacoeconomic 
assessments are not applied at the state level [25], the 
WHO has previously recommended to determine the 
acceptable value of economic feasibility based on the 
size of the gross domestic product (GDP) [26, 27]. If 
the cost per QALY is less than or equal to the value of 
GDP, then the technology is definitely economically 
feasible, even if it exceeds the value of GDP by 1-3 
times, technology is still considered economically 
expedient, if it exceeds more than 3 times – expense. In 
accordance with the WHO updated recommendation, a 
fixed rate of cost-effectiveness should not be used as a 
separate criterion for financing decision-making, price 
setting or reimbursement of the cost of a new medical 
product or other intervention.  
The gross domestic product (GDP) in 2019 
amounted to $3,464 per capita in Ukraine [28]. In our 
case, we received an additional QALY value of $4,729, 
which is 1.4 times the GDP per capita.  
According to the sensitivity analysis, it has been 
found that only in the case of a 50% reduction in the 
cost of the vaccine, it will be economically feasible (1 
QALY will be less than 2 GDP per capita). By changing 
the remaining sensitivity parameters, the results allow 
recommending the technology for implementation, 
considering the current economic situation in Ukraine. 
4.1. Restriction of research 
The study is characterized by several limitations. 
The high efficacy of vaccination against acute 
condyloma and other HPV-associated diseases (due to 
lack of reliable statistical data on morbidity) was not 
considered. Screening costs were not considered at 
cervical cancer (they were the same for both models). 
When assessing costs, tariffs for private clinics were 
used, which may differ from spending in other health 
care facilities. 
Modeling did not consider the population effect of 
vaccination, found in several countries where 
vaccination against HPV is included in the vaccination 
calendar. Also, there was no calculation of indirect 
costs (lost profits). The accounting of these factors 
would allow to predict the higher value of the cost of 
vaccination against the papillomavirus infection in 
Ukraine. This will be one of the areas for further 
research. 
5. CONCLUSION 
According to the results of the review of scientific 
sources, high efficiency (70-100%) of vaccination 
against HPV infection was determined in terms of the 
prevention of the occurrence of HPV associated 
diseases, including cervical cancer. 
Established with the help of Markov simulation, in 
the basic version, the cost of one additional year of 
quality of life during vaccination with a divalent 
vaccine will be $4,729 which is 1,4 times the per capita 
GDP in Ukraine. Taking into account the obtained 
results and the actual cost of the vaccine, the total 
vaccination against HPV infection to prevent cervical 
cancer in Ukraine is currently economically feasible. 
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